PLOS Biology

METHODS AND RESOURCES

A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanisms

Lohany Dias Mamede[1], Miwei Hu[2], Jaime Vaquer-Alicea[3], Amanda R. Titus[1], Patricia M. Passos[1], Erica Lantelme[4], Rachel L. French[5], Paige A. Kirschner[2], Marc I. Diamond[3], Timothy M. Miller[2], Yuna M. Ayala[1]*

1 Edward Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America, **2** Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, United States of America, **3** Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, Texas, United States of America, **4** Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States of America, **5** Agilent Technologies, Santa Clara, California, United States of America

* yuna.ayala@health.slu.edu

OPEN ACCESS

Citation: Mamede LD, Hu M, Vaquer-Alicea J, Titus AR, Passos PM, Lantelme E, et al. (2026) A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanisms. PLoS Biol 24(3): e3003662. https://doi.org/10.1371/journal.pbio.3003662

Academic Editor: Josh Dubnau, Stony Brook University Medical Center: Stony Brook University Hospital, UNITED STATES OF AMERICA

Received: March 22, 2025

Accepted: February 2, 2026

Published: March 24, 2026

Data availability statement: All relevant data can be found within the paper and Supporting information flies. Flow cytometry data are

Abstract

TDP-43 pathology is a hallmark of fatal neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and limbic-predominant age-related TDP-43-encephalopathy (LATE). In affected patients, cytoplasmic TDP-43 aggregates are accompanied by disruption of its normal nuclear localization and function. Because TDP-43 is an RNA binding protein that controls transcript processing, including repression of cryptic exon splicing, its loss leads to dysregulation of gene expression. Despite its central significance in disease, the connection between TDP-43 aggregation and dysfunction remains poorly understood, and models to study the underlying mechanisms are limited. Here, we characterize a robust and quantitative cell-based reporter that captures both aggregation and the resulting loss of function. Using this human biosensor cell line, we show that aggregation initiated by prion-like seeding drives progressive depletion of nuclear TDP-43 and induces signature features of diminished TDP-43 activity, such as increased DNA damage and activation of cryptic exon splicing. We find that aggregate seeding also induces cryptic exon splicing in human neurons implying that this pathological link extends to disease-relevant models. The seeding model provides a platform for dissecting mechanisms that underlie TDP-43 pathology and for identifying factors that modulate the aggregation-to-dysfunction transition. Our data shows that aggregate seeding impacts TDP-43 autoregulation, initiating a toxic feed-forward mechanism that disrupts TDP-43 homeostasis. Furthermore, reducing ataxin-2 levels decreases aggregation and restores TDP-43 activity. Together, these findings reveal a molecularly guided strategy to directly impact TDP-43 activity by decreasing its misfolding

available in Mendeley Data: V1, doi: https://doi.org/10.17632/yh788t3bxy.1.

Funding: This work was supported in part by National Institutes of Health (NIH) National Institute for Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA) grants R01 NS114289 (to Y.M.A.) (https://www.ninds.nih.gov/, https://www.nia.nih.gov/); the Department of Defense CDMRP/ALSRP W81XWH-20-1-0241 (to Y.M.A.) (https://cdmrp.health.mil/alsrp/default.aspx); Hamon Charitable Foundation (to M.I.D); Lyle Rakers Foundation (to T.M.M.). Healthy Aging and Senile Dementia [P01 AG003991], Alzheimer's Disease Research Center [P30 AG066444], Adult Children Study [P01 AG026276] to the Knight Alzheimer Disease Research Center at Washington University in St. Louis, Neuropathology Core. The sponsors did not play a role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; CEs, cryptic exons; CTD, C-terminal domain; DTT, dithiothreitol; FACS, fluorescence activated cell sorting; FBS, fetal bovine serum; FRET, Förster resonance energy transfer; FTD, frontotemporal dementia; FTLD-TDP, frontotemporal lobar degeneration; HEK293, human embryonic kidney cell line; KD, knocked-down; LATE, limbic-predominant age-related TDP-43-encephalopathy; NMD, nonsense-mediated decay; NTD, N-terminal domain; pTDP-43, phosphorylated TDP-43; qPCR, quantitative PCR; STED, stimulated emission depletion; TDP-43, Transactive Response DNA binding protein; TDPBR, TDP-43 3'UTR binding region.

and aggregation, highlighting approaches to prevent TDP-43 dysfunction and mitigate toxicity under pathological conditions.

Introduction

The Transactive Response DNA binding protein (TDP-43) is an essential RNA binding protein that regulates gene expression through RNA processing and is strongly linked to multiple neurodegenerative disorders, collectively referred to as TDP-43 proteinopathies. TDP-43 pathology is characterized by protein aggregation, most often in the cytoplasm of neurons and glial cells, and depletion from its normal nuclear distribution [1]. TDP-43 is an RNA binding protein most well-characterized for regulating alternative splicing and alternative polyadenylation [2–6]. Recent findings have underscored the involvement of loss of TDP-43 function in disease, as dysregulation of TDP-43 target genes is observed in patients affected by TDP-43 proteinopathies [7–12]. Together, these observations strongly suggest that TDP-43 misfolding and aggregation are correlated with the loss of protein function. However, the mechanisms connecting these two major components of TDP-43 pathology remain unclear.

TDP-43 pathology is a hallmark of neurotoxicity and neurodegeneration in almost all amyotrophic lateral sclerosis (ALS) and ~50% of frontotemporal lobar degeneration (FTLD-TDP) and the ensuing frontotemporal dementia (FTD) [1,13]. TDP-43 inclusions also characterize an Alzheimer's disease (AD)-associated disorder, limbic-predominant age-related TDP-43 encephalopathy (LATE), that affects nearly a quarter of individuals over 85 years of age [14]. In addition, TDP-43 is a comorbid feature of greater than 50% of AD cases, correlated with more aggressive memory loss and brain atrophy [15–18]. Similarly, TDP-43 aggregates are major components upon traumatic brain injury and chronic traumatic encephalopathy [19,20]. A common mechanism thought to contribute to pathogenesis in TDP-43 proteinopathies and other neurodegenerative disorders is the propagation of protein toxicity through prion-like aggregate seeding. In this process, misfolded protein serves as a template to induce the aggregation of its soluble species, creating a self-perpetuating cycle. Experimental evidence demonstrates that aggregates generated from purified TDP-43 are seeding-competent in cell culture models [21,22]. Additionally, insoluble extracts derived from ALS and FTD CNS tissue initiate de novo aggregation in cellular models and iPSC-derived cerebral organoids [23,24]. Additional compelling evidence for TDP-43 seeding activity comes from TDP-43 transgenic mouse models in which injection of FTD-derived extracts enriched in phosphorylated TDP-43 (pTDP-43) leads to the spread of pathology [25]. These observations align with clinicopathological evidence showing the progressive spread of neuronal loss and TDP-43 pathology in the CNS of ALS and FTD patients [14,17,26–29]. Hence, these studies strongly support the model that TDP-43 aggregates propagate toxicity and thereby contribute to neurodegeneration. The mechanisms of proteopathic seed uptake, propagation and the consequences of aggregate seeding on TDP-43 cellular function remain poorly understood. Further elucidation of these processes will highlight underlying disease mechanisms and identify potential therapeutic strategies.

The C-terminal domain (CTD) of TDP-43 plays a critical role in aggregation and aggregate propagation, as demonstrated by the highly enhanced seeding efficiency of exposed fibrillar CTD fragments generated through limited proteolysis of full-length aggregates [30]. The CTD is a mostly disordered domain referred to as the prion-like domain for its sequence similarity to yeast prion proteins [31]. Furthermore, structural studies of aggregates isolated from FTD patient brain have shown that the core of the pathological filament is formed by the central portion of the CTD, specifically amino acids 282–360 [32–34] (Fig 1A). These observations strongly implicate a central role of this region during misfolding and transmission of disease-relevant aggregates.

Experimental methods to recapitulate TDP-43 aggregation and loss of function in the same model have been challenging to develop and remain rare. To induce TDP-43 aggregation, common models rely on overexpression of wild-type or mutant TDP-43 or chemical treatment to induce oxidative stress or other proteotoxic conditions. These models trigger generalized disruption of cell function and undermine insight into disease-relevant processes. Furthermore, these experimental conditions rarely lead to TDP-43 depletion, and their effect on TDP-43 function has not been widely reported. Other assays to investigate TDP-43 dysfunction rely on knocking-out/down TDP-43 expression, however, these conditions lack the contribution of TDP-43 mislocalization and aggregation. Thus, to establish cellular models combining both TDP-43 aggregation and loss of protein function mechanisms that overcome the limitations of previous methods, we explored systems based on TDP-43 prion-like aggregate seeding. Using FTD brain-derived seeds to induce aggregation in a FRET-based reporter cell line, we find that seeding greatly impacts TDP-43 localization and leads to gradual loss of function. Our model recapitulates key features of TDP-43 pathology and provides evidence that aggregation, mislocalization and loss of function mechanisms are interconnected. Furthermore, we identify processes that become altered upon aggregate seeding and identify key factors that modulate both aggregation and dysfunction.

Results

TDP-43 aggregate seeding triggers de novo *aggregation and gradual TDP-43 mislocalization*–To quantify, isolate and characterize cells affected by TDP-43 aggregates induced by intracellular seeding, we employed a human embryonic kidney cell line (HEK293) that reports TDP-43 aggregation based on Förster resonance energy transfer (FRET) [35]. This cell line stably expresses the TDP-43 C-terminal domain (CTD, amino acids 262-414) C-terminally fused to FRET pairs mClover3 and mRuby3 (HEK293^{FRET}) (Fig 1A). To investigate TDP-43 aggregate seeding in the context of disease-derived proteopathic seeds, we isolated the insoluble fraction of autopsy brain from FTLD-TDP patients subtypes A and B [36–43]. For these studies we utilized frontal cortex tissue primarily from four different cases. We prepared sarkosyl-insoluble fractions upon sequential extraction based on previously established methods [44]. Herein, we refer to this extract as FTD seeds. These samples were enriched for total TDP-43 and a marker of pathological inclusions, phosphorylated TDP-43 (pTDP-43, Ser409/410) [45] (S1A Fig). As control, we processed brain tissue from three neurologically unaffected individuals, which did not show significant increase of pTDP-43. Treatment of HEK293^{FRET} cells with FTD seeds induced the formation of cytoplasmic inclusions composed of mClover and mRuby-CTDs that strongly accumulated pTDP-43, as seen by immunofluorescence (Fig 1B). In addition, biochemical fractionation into RIPA-soluble and Urea-soluble fractions indicated strong pTDP-43 upregulation in cells treated with FTD seeds, compared to control extract (S1B Fig). Moreover, pTDP-43 was highly enriched in the Urea-soluble fraction, consistent with aggregate formation. We observed recruitment of the ubiquitin-binding protein 62/sequestosome 1 (p62/SQTM1) to cytoplasmic aggregates which, together with pTDP-43 accumulation, is commonly associated with TDP-43 inclusions in disease (Fig 1C) [36,46]. Intriguingly, the aggregates often showed filament-like morphology, as seen by high-resolution microscopy (Fig 1D) and confocal imaging (S2A Fig), suggesting that de novo aggregation follows a defined structural pattern upon seeding. Whether these structures resemble TDP-43 filaments in FTD patient brains remains an open question for future investigation [32–34]. Analogous cell lines expressing only mClover- or mRuby-fused CTD showed similar aggregate seeding behavior (S2B Fig). Next, we quantified the number of cells that developed aggregates upon seeding by flow cytometry and determined the



Fig 1. Disease-derived extract strongly activates TDP-43 aggregate seeding in a sensitive FRET-based biosensor. A) The HEK293^{FRET} cell line stably expressing the TDP-43 C-terminal domain (CTD, amino acids 262-414) fused to mClover3 and mRuby3 FRET pairs was used as a reporter of TDP-43 aggregation upon seeding with FTD extract, prepared as in S1A Fig. Image created in BioRender, Ayala, **Y.** (2026) https://BioRender.com/

kt5mypg. B) de novo CTD aggregation in HEK293^{FRET} cells treated with FTD seeds visualized by confocal fluorescence microscopy. As control, cells were treated with neurologically unaffected tissue extract. Phosphorylated TDP-43 (pTDP-43) and p62, shown in **(C)**, were used as markers of pathological TDP-43 aggregates. DAPI staining was used to highlight nuclei. **D)** High resolution images of aggregates in cells treated with FTD seeds as z-stacks with DAPI overlay generated with stimulated emission depletion (STED) microscopy. The white box corresponds to the enlarged region. Scale bar for microscopy images, 10 μm. **E)** Flow cytometry to quantify FRET-positive and FRET-negative HEK293^{FRET} cells six days post-seeding. The raw data can be found in Mendeley Data, V1, https://doi.org/10.17632/yh788t3bxy.1 Percent over total of FRET-positive cells and FRET median fluorescence intensity (MFI) from the representative experiments are shown. **F)** Average percent FRET-positive cells treated with FTD seeds and control extract quantified by flow cytometry. **(G)** Calculated integrated FRET density equal to the product of MFI and %FRET-positive cells. SEM in both (F) and **(G)**, n > 3, *p = 0.028, Mann-Whitney test. The data underlying this figure can be found in S1 Data.

https://doi.org/10.1371/journal.pbio.3003662.g001

ratio of FRET-positive cells relative to total. Treatment with FTD seeds resulted in an average of 14% FRET-positive cells, compared to <1% for control tissue extract (Fig 1E and 1F). This correlated to a dramatic increase in integrated FRET density, compared to control extract (Fig 1G). The large increase in this value, which measures the number of FRET-positive cells and the degree of aggregation in each cell, highlights the sensitivity of the assays to measure aggregate accumulation [47]. These findings are consistent with the previously observed response of this reporter cell line to seeding with pre-formed aggregates of purified TDP-43 and aggregates derived from a mouse model of TDP-43 pathology in skeletal muscle [24,35]. The significant increase in FRET activity upon treatment with FTD seeds, compared to control-treated cells, in which this signal is nearly absent, suggests that homotypic reversible CTD interactions, such as phase separation [48,49], do not significantly contribute to the FRET signal detected in our analyses. It is also possible that, under the conditions tested, the concentration of CTD fragments in HEK293^{FRET} cells does not reach the threshold required for condensate formation or phase separation.

To rule out a contribution of FRET signal from interactions between mClover and mRuby proteins in the absence of the CTD, we tested stable HEK293 cells expressing the CTD fused to mClover or mRuby alone or in combination with mRuby or mClover proteins lacking the CTD, respectively (S3A Fig). These multiple cell lines were transfected with either FTD seeds, tau-positive AD extract, lipofectamine and media only controls. After 48 hours, only HEK293^{FRET} cells expressing both the CTD-mClover and mRuby fusion proteins generated significant FRET signal upon treatment with FTD-derived extract (S3B and S3C Fig). All other cell lines showed negligible FRET values. Previous findings together with new control experiments demonstrate that the HEK293^{FRET} reporter specifically responds to TDP-43 proteopathic seeds. Seeding with α-synuclein pre-formed fibrils fail to induce significant FRET signal [24]. Similarly, we find no significant FRET signal in cells treated with insoluble brain extract from tau-positive Alzheimer's disease cases lacking TDP-43 pathology (S3C Fig). Together, these results indicate that de novo TDP-43 aggregation in this biosensor cell line is specifically induced by proteopathic seeds derived from tissue with TDP-43 pathology, while remaining insensitive to other protein aggregates. Furthermore, the FRET signal generated in HEK293^{FRET} cells depends on the presence and aggregation of the CTD.

We next investigated changes in the localization of endogenous TDP-43 following seeding-induced aggregation. To specifically detect endogenous TDP-43, we used an antibody recognizing an N-terminal domain (NTD) epitope absent in mClover- and mRuby-CTD constructs. We confirmed that the signal detected by the TDP-43 NTD-specific antibody does not arise from internalized FTD-derived seeds by examining HEK293 and HEK293^{FRET} cells six and two days post-seeding, respectively. No significant cytoplasmic TDP-43 NTD-specific antibody signal was detected in these cells (S4A and S4B Fig). In addition, during our seeding experiments, cells were trypsinized and replated 24 hours post-transfection with FTD seeds or control extract to remove any non-internalized aggregates. These experiments indicate that the amount of internalized FTD seeds is insufficient to generate detectable immunofluorescence with the NTD antibody under our experimental conditions. Despite the accumulation of cytoplasmic aggregates in HEK293^{FRET} cells three days post-treatment with FTD seeds, endogenous TDP-43 localization remained largely unaffected (Fig 2A, arrows). In contrast, by six days post-seeding, we observed colocalization of endogenous TDP-43 with CTD cytoplasmic inclusions, accompanied by marked reduction of its nuclear localization (Fig 2B). To quantify depletion of nuclear TDP-43 distribution in cells treated



Fig 2. Aggregate seeding induces co-aggregation and gradual depletion of nuclear endogenous TDP-43. A) Immunofluorescence of HEK293^{FRET} cells treated with FTD seeds or neurological unaffected tissue extract, as control, probed with a TDP-43 antibody targeting an N-terminal domain epitope to detect endogenous protein only. Cells were imaged by confocal microscopy three and six days post treatment in **(B)**. Dashed lines delineate cell boundaries and arrows indicate cells affected by cytoplasmic aggregates. The nuclei of aggregate-affected cells treated with FTD seeds at six days post seeding are highlighted by solid yellow lines. Scale bar, 10 μm. **C)** Mean fluorescence intensity of nuclear endogenous TDP-43 in cells six days post treatment with FTD seeds, comparing cells with and without cytoplasmic aggregates. ImageJ was used to quantify pixel intensity per nuclear area, defined by DAPI staining. Calculated mean values, SEM, of >250 cells from n = 5 are shown, **p = 0.001, paired t *t*est. The data underlying this figure can be found in S2 Data.

https://doi.org/10.1371/journal.pbio.3003662.g002

with FTD seeds, we measured the mean fluorescence intensity of endogenous TDP-43 in the region of interest defined as the nucleus. We found that nuclear endogenous TDP-43 decreased by approximately 70% percent in cells with cytoplasmic aggregates, compared to cells without observable aggregates (Fig 2C). These findings indicate that seeding-initiated cytoplasmic CTD aggregation sequesters endogenous TDP-43, leading to its gradual depletion from the nucleus, thus recapitulating key features of neuronal TDP-43 pathology in patients [1].

Aggregate seeding results in loss of TDP-function in affected cells—We then examined whether the loss of nuclear TDP-43 in aggregate-affected cells correlates with loss of TDP-43 function. First, we compared the impact on genomic stability, as TDP-43 downregulation increases accumulation of DNA damage and genomic instability in human cells, including neurons [50–53]. Six days post-seeding, phosphorylated histone H2AX (γH2AX), a marker of DNA breaks, increased and was detected in 50 ± 7% of TDP-43 aggregate-positive cells (>15 γH2AX foci per nucleus) (Fig 3A). In contrast, control-treated cells showed 4% γH2AX-positive nuclei. Furthermore, immunoblotting showed a significant 2.5-fold increase in γH2AX levels upon seeding with FTD-derived extract, compared to control extract (Fig 3B). To explore whether DNA damage is linked to the seeding-induced loss of nuclear TDP-43, we quantified γH2AX and nuclear TDP-43 after treatment of stable HEK293 cells expressing mClover-CTD with FTD seeds (S4C Fig). Our results showed a significant



Fig 3. Seeding-induced aggregation increases DNA damage corresponding to decreasing nuclear TDP-43 localization. A) Immunofluorescence obtained by confocal microscopy to detect γH2AX, a marker of DNA breaks, in cells six days post treatment with control or FTD seeds. Arrow points to the accumulation of γH2AX in aggregate-affected cells. Scale bar, 10 μm. As negative control, cells were treated with neurological unaffected tissue extract. B) γH2AX levels quantified by immunoblotting in cells treated with FTD seeds and control, plotted as mean, SEM of n = 6. Mann-Whitney test, **p = 0.002. GAPDH was used as loading control. **C)** Mean γH2AX and nuclear endogenous TDP-43 fluorescence intensity (defined by DAPI staining) quantified from images in S4C Fig (ImageJ). Values were calculated for >50 cells per replicate for n = 3. The Pearson correlation coefficient (*r*) and p-value are shown. The data underlying this figure can be found in S3 Data and the original image can be found in S1 Raw Images.

https://doi.org/10.1371/journal.pbio.3003662.g003

inverse correlation between the mean fluorescence intensity of TDP-43 and γH2AX in the nucleus, whereby decreasing nuclear TDP-43 levels are associated with increasing γH2AX detection and vice versa in a linear relationship (Fig 3C). These results strongly suggest that aggregation progressively depletes functional TDP-43. Moreover, these observations imply that the link between TDP-43 dysfunction and loss of genomic integrity may be extended to conditions triggered by seeding and TDP-43 mislocalization.

To further examine TDP-43 activity in cells affected by aggregate seeding, we measured mRNA transcript expression and processing of TDP-43-regulated targets. FRET-positive and FRET-negative cells were isolated via fluorescence activated cell sorting (FACS) at six days post-seeding with FTD seeds (Fig 4A). Cells treated with control tissue extract or non-treated control were also sorted, resulting in mostly FRET-negative cells. Based on previous studies in human cells, we selected transcripts controlled by TDP-43 through different posttranscriptional processing mechanisms. TDP-43 inhibits the expression of *SMCA1* and *GXYLT1* through binding to the 3'UTR and controlling the usage of alternative polyadenylation poly(A) sites [6] (Fig 4B). Using real-time quantitative PCR (qPCR), we measured mRNA expression in cells treated with FTD seeds, control-derived extracts and non-treated control. FRET-positive cells showed approximately 2-fold or greater significant increase in mRNA expression, compared to FRET-negative cells (Fig 4B). Actin B mRNA (*ACTB*) served as reference for a transcript that is not regulated by TDP-43 and showed no significant differences in expression between groups. Similar analysis at earlier time points (three days post-seeding) when approximately 4% of cells treated with FTD seeds were FRET-positive, showed no significant changes in *SMCA1*, *GXYLT1* expression between FRET-positive and negative groups (S5A Fig).

In addition to regulating the constitutive splicing of hundreds of genes, TDP-43 inhibits or enhances splicing of cryptic exons (CEs), which constitute untranslated/intronic regions that are normally excluded from mature mRNA [7]. Recent studies show the inclusion of TDP-43 target CEs in ALS-FTD cases and AD, consistent with loss of TDP-43 function [9–12,54–57]. Thus, impaired regulation of CE splicing is viewed as a salient feature of TDP-43 dysfunction and disease, and abnormal mRNA products may be used as sensitive markers of TDP-43 pathology in patients. We investigated activation of CEs upon TDP-43 aggregate seeding in cases where TDP-43 inhibits their inclusion, *HDGFL2* and *ARHGAP32* (Fig 4C) [7,58]. We observed CE splicing in cells treated with FTD seeds starting at three days post-treatment, *ARHGAP32* CE splicing was significantly upregulated and *HDGFL2* CE splicing showed an increasing trend. These non-sorted cells showed nearly 2-fold greater CE inclusion compared to control. Strikingly, FRET-positive cells isolated six days post-seeding showed 150 and 1,000-fold greater *HDGFL2* and *ARHGAP32* CE inclusion, respectively, compared to FRET-negative and control-treated cells (Fig 4D). In contrast, we found no significant differences in the levels of *HDGFL2* and *ARHGAP32* transcripts lacking the CEs between the experimental groups (S5B Fig). The significant activation of CE inclusion starting at early timepoints after aggregate seeding, which dramatically increases in aggregate-affected cells, implies that CE regulation of these targets is highly sensitive to decreasing TDP-43 levels.

To test whether aggregate seeding induces pathological markers of TDP-43 aggregation (pTDP-43, p62) and loss of TDP-43 function in a different cell line, independent of CTD expression, we first investigated seeding in HEK293 cells without overexpression of exogenous TDP-43, mutant or fragment. At one week post transfection with FTD seeds we observed no significant cytoplasmic aggregation or loss of endogenous TDP-43 levels, compared to control. The number or size of the aggregates did not change with longer incubation times (up to six weeks) in which case cells were replated weekly to prevent overcrowding and cell death. These findings indicate that seeding-induced aggregation may not be observed upon expression of endogenous TDP-43 alone or without adding proteotoxic stress conditions, within the experimental timeline tested. Furthermore, these results suggest that misfolded TDP-43 is normally cleared efficiently by the proteasomal degradation and autophagy pathways. Disruptions of these clearance mechanisms, additional proteotoxic stress, impaired nuclear-cytoplasmic trafficking, accumulation of C-terminal fragments, or other unknown factors may be required to promote aggregation-induced nuclear depletion and dysfunction. Therefore, we tested the HEK293$^{TDP\text{-}43NLS}$ cell line, expressing a single copy of the nuclear localization-deficient full length mutant TDP-43^{NLS} [21]. We previously showed



Fig 4. Aggregate seeding impairs TDP-43–dependent RNA processing. A) Experimental scheme to isolate FRET-positive (FRET+) and -negative (FRET-) HEK293^{FRET} biosensor cells by FACS six days post transfection with FTD seeds, or neurologically unaffected tissue extract and compared to

non-treated control. Image created in BioRender, Ayala, **Y.** (2026) https://BioRender.com/yy466ls. **B)** TDP-43 regulates 3′ UTR processing and polyadenylation choice via direct recruitment to transcripts, whereby TDP-43 binding inhibits *SMC1A and GXYLT1* mRNA expression. Relative *SMC1A* and *GXYLT1* mRNA levels were measured by quantitative real-time PCR (qPCR) and normalized to non-treated sample. *ACTB* served as TDP-43-independent transcript control. Graphs represent mean values, SEM of n > 4, analyzed by unpaired one-way ANOVA, *p = 0.02, **p = 0.009, ***p < 0.0002, ns, non-significant. **C)** Cryptic exon (CE) splicing is normally suppressed by TDP-43 in *HDGFL2* and *ARHGAP32*. Relative CE inclusion quantified by qPCR from non-sorted HEK293^{FRET} cells collected three days post treatment with FTD seeds and controls. Values were normalized to non-treated samples, mean SEM for n = 5, analyzed with non-parametric, unpaired t test, **p < 0.008, ns, non-significant. **D)** Relative *HDGFL2* and *ARHGAP32* CE inclusion quantified in sorted cells six days post seeding, normalized to non-treated control. Mean SEM for n = 5, ****p < 0.0001, according to unpaired one-way ANOVA. **E)** Immunofluorescence confocal microscopy of neurons derived from neurogenin-2 (*Ngn2*)-inducible human induced pluripotent stem cells (iNeurons), DIV15. iNeurons incubated with control extract or FTD seeds post-differentiation and collected after 2-3 weeks were stained for MAP2 and Tuj1 to evaluate neuronal differentiation. Scale bar, 100μm. **F)** *MAP2AB* expression was measured by qPCR. **G)** *ARHGAP32* relative CE inclusion and relative expression of truncated *STMN2* quantified by qPCR. Graphs represent mean values, SEM of n > 5. *p = 0.01, ns, non-significant, non-parametric, unpaired t test. *GAPDH* was used as reference in all experiments. The data underlying this figure can be found in S4 Data and the original image can be found in S1 Raw Images.

https://doi.org/10.1371/journal.pbio.3003662.g004

that TDP-43^{NLS} undergoes de novo aggregation following transfection with TDP-43 aggregates derived from full-length purified protein [21]. Seeding with FTD seeds increased cytoplasmic aggregation recognized by pTDP-43 [21] and p62, which were absent in control-treated cells (S6A Fig). Furthermore, we found upregulation of CE splicing, compared to control, suggesting loss of normal TDP-43 function upon aggregate seeding (S6B Fig). These results indicate that the strong link between loss of function and aggregation is not specific to the expression of CTD fragments.

Next, we investigated whether TDP-43 aggregate seeding elicits loss of function in human neurons, as a more disease-relevant model. Induced pluripotent stem cells (iPSCs) with a doxycycline-inducible neurogenin-2 transgene integrated at the AAVS1 locus were differentiated into neurons (iNeurons) [59,60] and treated with FTD seeds or control one week post-differentiation (Fig 4E). iNeurons incubated for two to three weeks after treatment with FTD seeds or control extract showed comparable *MAP2AB* expression (Fig 4F), indicating similar neuronal differentiation and maturation. Treatment with FTD seeds induced a significant upregulation of *ARHGAP32* CE inclusion relative to control treated cells (Fig 4G), suggesting that seeding-induced TDP-43 loss of function may be triggered in human neurons. We also observed increased expression of truncated *STMN2*, although this change did not reach statistical significance.

Aggregate seeding disrupts TDP-43 homeostasis through its impact on autoregulation—We next investigated whether TDP-43 functional defects triggered by aggregate seeding impact TDP-43 autoregulation, a critical process controlling TDP-43 homeostasis. TDP-43 regulates its own mRNA (*TARDBP*) and protein levels through a negative feedback loop that requires TDP-43 recruitment to the *TARDBP* 3'UTR within exon 6 [5,61](Fig 5A). This binding downregulates *TARDBP* mRNA expression by activating alternative poly(A) site usage, splicing and mRNA sequestration, which, combined, decrease protein expression [5,61,62]. Low TDP-43 levels enhance usage of the proximal poly(A) site (pA_1) and inhibits removal of alternative introns 6, 7 and 8 through splicing, overall increasing Short 3'UTR transcript expression and protein synthesis [62]. On the other hand, excess TDP-43 protein increases the accumulation of multiple transcript isoforms that are targets of nonsense-mediated decay (NMD), as well as the Long 3'UTR which is a product of distal poly(A) site (pA_4) selection that becomes sequestered in nuclear particles [5,62–64]. Maintaining physiological TDP-43 proteostasis through this evolutionarily conserved process is important for cell function as both diminished TDP-43 and elevated protein levels result in misregulated target expression. Moreover, abnormally increased TDP-43 concentration disrupts self-assembly and promotes aggregation ([65] for review). To determine whether aggregate seeding alters TDP-43 autoregulation, we compared *TARDBP* mRNA expression in FRET-positive and FRET-negative HEK293^{FRET} cells treated with FTD seeds. We also sorted cells treated with control tissue extract as well as non-treated control. We found greater than 2-fold significant upregulation of *TARDBP* mRNA expression in FRET-positive, compared to FRET-negative cells treated with FTD seeds by qPCR (Fig 5B). This significant increase was also observed relative to control cells, which were almost all FRET-negative. Similar results were obtained using primers for qPCR that are common to Short and Long 3'UTR mRNA isoforms, Ex 2–3, and primers for Short 3'UTR (Ex 6) that do not recognize the NMD-sensitive isoforms.



Fig 5. Aggregate seeding impacts TDP-43 autoregulation. A) Autoregulation is mediated by TDP-43 protein binding to the TDP-43 Binding Region (TDPBR, red) within the 3'UTR of its own transcript, upstream of the proximal polyadenylation site (pA_1) and near exon 6 splice sites (dashed lines indicate splicing events). TDP-43 recruitment promotes distal polyadenylation site (pA_4) usage and exon 6 splicing to generate isoforms which become targets for nonsense-mediated decay (NMD). In the absence of TDP-43 binding, the Short 3'UTR isoform is upregulated, resulting in increased protein expression. Indicated are the positions of primers for qPCR assays. Image created in BioRender, Ayala, **Y.** (2026) https://BioRender.com/pcvor00. **B)** Relative endogenous *TARDBP* mRNA expression quantified by qPCR in FACS-sorted FRET-positive (FRET+) and negative (FRET-) cells, six days after treatment with FTD seeds. *GAPDH* was used as reference. For each replicate, values were normalized to non-treated sample, mean and SEM are shown for n = 5. ****p < 0.0001, ns = non-significant, according to unpaired one-way ANOVA. The data underlying this figure can be found in S5 Data.

https://doi.org/10.1371/journal.pbio.3003662.g005

This primer pair captures the TDP-43 3'UTR binding region (TDPBR) upstream of pA_1. In contrast, primers detecting the region closely upstream of the $polyA_4$ (distal), specific for the Long 3′ UTR isoform, did not show significant differences in expression. These results suggest that aggregate seeding specifically upregulates pA_1 usage and inhibits exon 6 splicing, thereby increasing expression of the Short 3'UTR isoform, consistent with a loss of active TDP-43. This expression profile is consistent with that observed in FTD/ALS patient-derived cells devoid of nuclear TDP-43 [8,62] and previous evidence showing specific upregulation of Short 3'UTR upon TDP-43 knockdown [62]. We next examined whether upregulation of the Short 3'UTR transcript in cells accumulating cytoplasmic aggregates correlates with increased TDP-43 protein expression. Unexpectedly, we detected no significant differences in protein levels between FRET-positive and FRET-negative sorted cells five days post-seeding (S7 Fig). The discrepancy between elevated Short 3'UTR transcript levels and unchanged protein expression may be due to activation of protein clearance mechanisms specifically in seeding-impacted cells, resulting in enhanced degradation of newly synthesized TDP-43. This hypothesis is supported by the recent report by Rummens and colleagues, which showed upregulation of genes involved in proteasomal and autophagosomal pathways in cells exposed to TDP-43 aggregate seeds [66].

TDP-43 aggregates specifically colocalize with modulators of aggregate seeding—Our findings showing strong co-localization of endogenous TDP-43 with cytoplasmic aggregates upon seeding (Fig 2B) led us to explore whether this recruitment is specific to TDP-43 and whether these inclusions act as sinks for proteins that interact with TDP-43 under normal and pathological conditions. We focused on RNA binding proteins with disordered or prion-like domains that interact with TDP-43 during RNA processing, stress granule assembly, or disease-associated conditions: hnRNP A2/B1, hnRNP C1/C2, hnRNP H1, FUS, matrin 3, SFPQ, G3BP1, TIAR, HSPB1, and ataxin-2 [67–71]. Detection of these proteins in non-treated control cells is shown in S10 Fig. Six days after treatment with FTD seeds we observed no significant colocalization of most proteins tested (Figs 6, S8A and S8B). These findings suggest that seeding-induced aggregates in $HEK293^{FRET}$ cells do not recruit proteins indiscriminately, even if these interact with TDP-43 under physiological conditions or during stress granule assembly. In contrast, ataxin-2 (*ATXN2*) and the small heat shock protein-1 (*HSPB1*) strongly colocalized with de novo cytoplasmic aggregates (Figs 7A and S8C arrows).

Previous reports showed that *ATXN2* alters TDP-43 aggregation and toxicity in disease-relevant models [72,73]. This and our observations of ataxin-2 colocalization with TDP-43 cytoplasmic aggregates (Fig 7A) led us to examine whether *ATXN2* expression influences seeding-induced TDP-43 aggregation. We knocked-down (KD) *ATXN2* expression by siRNA in $HEK293^{FRET}$ cells, following treatment with FTD seeds, achieving approximately 50% reduction or greater in *ATXN2* mRNA and protein levels, compared to non-targeting control siRNA (S9A-C Fig). Decreasing *ATXN2* expression significantly reduced the accumulation of FRET-positive cells and integrated FRET density six days after treatment with FTD seeds (Fig 7B). *ATXN2* KD did not significantly change the number of FRET-positive cells upon treatment with control tissue extract, which accounted for <1% of all cells (S9D Fig). Additionally, we found that *ATXN2* KD significantly increased nuclear endogenous TDP-43 [21] in cells that were treated with FTD seeds, compared to control siRNA treatment (Fig 7C). These results suggest that reducing ataxin-2 levels by 50% or greater suppresses the loss of nuclear TDP-43 triggered by aggregation. To determine whether *ATXN2* downregulation suppresses aggregation-induced TDP-43 loss of function, we measured *ARHGAP32* and *HDGFL2* CE inclusion, following *ATXN2* KD. Six days post-transfection with FTD seeds, CE splicing significantly decreased by greater than 25% for both transcripts upon *ATXN2* KD, compared to siRNA control (Fig 7D). In contrast, *ATXN2* downregulation did not significantly alter CE splicing in cells treated with control extract. Together, our results suggest that ataxin-2 promotes seeding-induced TDP-43 aggregation as well as the ensuing loss of TDP-43 function. These observations are consistent with previous studies showing that *ATXN2* enhances TDP-43 aggregation and neurotoxicity in human cells and animal models [72,74], and suggest that ataxin-2 potentiates the link between TDP-43 aggregation and depletion of cellular function. Based on our findings, specific protein recruitment to de novo TDP-43 aggregates in this system may indicate interactions that contribute to TDP-43 pathology.



Fig 6. Protein partners that normally bind TDP-43 are not recruited to seeding-induced aggregates. Representative immunofluorescence images, obtained by confocal microscopy, of HEK293^{FRET} cells treated with FTD seeds detecting RNA binding proteins that form complexes with TDP-43 under physiological conditions. Neurological unaffected tissue extract was used as control. Images of non-treated control are shown in S10 Fig. Scale, 10 μm, n > 3. DAPI staining was used to highlight nuclei.

https://doi.org/10.1371/journal.pbio.3003662.g006

Discussion

TDP-43 aggregate accumulation combined with mislocalization and loss of function are central features of TDP-43 proteinopathies. However, direct evidence linking these processes and understanding the mechanisms that mediate them remain limited, and tractable models to address these outstanding questions are not widely available. Here, we characterized a highly robust and sensitive biosensor cell line that enables quantification, isolation and analysis of cells affected by TDP-43 aggregate seeding. Our findings strongly support the model in which cytoplasmic aggregation gradually sequesters cellular TDP-43, reducing its nuclear localization and function. This reporter system provides a powerful platform for elucidating mechanisms that regulate the pathogenic connection between aggregation and loss of function.

Our findings that aggregate seeding triggers TDP-43 dysfunction are supported by recently published work from the Polymenidou and Da Cruz laboratories [66,75]. Scialo, Rummens and colleagues conducted seeding experiments using fibrils of purified TDP-43 CTD to efficiently induce aggregation. In our studies, the reporter cell line stably expresses a similar fragment and responds robustly to seeding with FTD-derived aggregates. These results, together with structural studies showing that the CTD forms the core of TDP-43 aggregates in disease brain [32–34], indicate that the CTD is a



Fig 7. Ataxin-2 specifically colocalizes with seeding-induced aggregates promoting their accumulation and loss of TDP-43 function. A) Immunofluorescence of HEK293^{FRET} cells treated with FTD seeds and probed with ataxin-2 antibody after six days, obtained by confocal microscopy. Neurological unaffected tissue extract was used as control. Images of non-treated control are shown in S10 Fig. Ataxin-2 colocalization with TDP-43 CTD aggregates is denoted by arrows. Scale bar, 10 μm, n = 3. **B)** Two days after treatment with FTD seeds, HEK293^{FRET} cells were transfected with

siRNA to down-regulate *ATXN2* or non-targeting siRNA, as negative control (S9A-C Fig). FRET-positive cells (% of total) quantified by flow cytometry and integrated FRET density are shown for n = 5. **p = 0.009, *p = 0.03, Mann-Whitney test. **C)** The mean fluorescence intensity of endogenous TDP-43 levels in the nucleus in cells treated with FTD seeds was quantified upon treatment with *ATXN2* and control siRNA (S9E Fig). Nuclei were defined by DAPI staining of >380 cells from three independent experiments. Mean, ***p = 0.0008, Mann-Whitney test. **D)** Relative *HDGFL2* and *ARHGAP32* CE inclusion measured by qPCR, using *GAPDH* as reference. For each replicate, values were normalized to non-treated sample. Mean and SEM for n = 4 analyzed by one-way ANOVA, *p < 0.02, **p < 0.001, ns = non-significant. The data underlying this figure can be found in S6 Data.

https://doi.org/10.1371/journal.pbio.3003662.g007

critical determinant of TDP-43 amplification and loss of function. Collectively, these studies provide compelling evidence that aggregation-triggered TDP-43 dysfunction is not cell-type specific and can be initiated by multiple forms of proteopathic seeds. Whether the pathways and aggregate structures activated upon seeding differ depending on the type of nucleating seed or cellular model used remains to be elucidated.

Dysregulation of TDP-43 target expression in ALS/FTD patients strongly supports the idea that loss of TDP-43 function significantly contributes to neurodegeneration. Several TDP-43 regulated genes are connected to essential neuronal function and their aberrant expression may underlie disease mechanisms (e.g., *STMN2, UNC13A, KALRN, KCNQ2*) [9,55,76–79]. In some cases, these mis-splicing events may serve as sensitive markers for TDP-43 dysfunction and pathology (e.g., *HDGFL2*) [12,57]. We demonstrate that aggregate seeding also impacts TDP-43 function in human neurons (Fig 4G), suggesting that this process may be observed in disease-relevant cell types. These findings are unique as pathogenic conditions which drive TDP-43 dysfunction in human neurons have not been widely reported.

We surveyed the effect of aggregate seeding in the expression of mRNA transcripts regulated by TDP-43–3'UTR processing/alternative polyadenylation and cryptic exon splicing. Cryptic exon splicing in HEK293^{FRET} cells was markedly more sensitive to seeding compared to alternative polyadenylation, as CEs are detected at earlier timepoints after seeding, even when cytoplasmic CTD aggregates are observed in only 4% of cells (Fig 4C). These observations suggest that certain TDP-43-dependent processing events are more sensitive to changes in TDP-43 expression, potentially reflecting differences in how TDP-43 interacts with the RNA in various regulatory settings. The defects resulting from seeding-induced loss of function extend to genomic instability, as reduced nuclear TDP-43 directly correlates with increased DNA damage. This finding is consistent with previous reports of elevated DNA damage in cerebral organoids upon seeding with ALS-derived extract [23], and aligns with studies highlighting the critical role of TDP-43 in maintaining genomic integrity. Together, these data support the idea that impaired genomic integrity may be a defining feature of TDP-43 proteinopathies.

The importance of TDP-43 autoregulation in maintaining physiological proteostasis has been postulated since the discovery of this negative feedback loop [5,61]. Its critical role in disease is further supported by data obtained from ALS/FTD patient-derived cells that lack nuclear TDP-43 and display dysregulated *TARDBP* transcript expression [8]. Here, we demonstrate that prion-like TDP-43 seeding impacts autoregulation by reducing functional protein levels. The upregulation of *TARDBP* transcript conducive to protein synthesis in FRET-positive cells, however, does not correspond to elevated TDP-43 protein expression. These results suggest that enhanced protein clearance mechanisms, which become activated in seeding-affected cells [66], rapidly degrade newly synthesized TDP-43. Therefore, under conditions impairing protein clearance, which are commonly associated with aging and neurodegeneration, aggregate seeding may initiate a toxic feed-forward loop that destabilizes protein homeostasis and amplifies aggregation.

We find that many proteins which physiologically interact with TDP-43 are not recruited to TDP-43 inclusions under the conditions tested (Fig 6). This includes hnRNPs that assemble through disordered domain contacts during splicing regulation (e.g., hnRNP A, hnRNP C) [68], suggesting that de novo TDP-43 aggregation initiated by prion-like seeding is a highly specific process. Additionally, the lack of significant colocalization of stress granules markers G3BP1 and TIAR with the cytoplasmic aggregates is consistent with growing evidence that stress granules are not direct precursors or required for TDP-43 aggregate formation [71,80]. Our observations indicate that prion-like seeding uniquely affects TDP-43 and other

proteins, which remain currently undefined. We identified one such interactor, ataxin-2, which enhances TDP-43-mediated toxicity in an animal model [74], and observed its strong colocalization with TDP-43 inclusions (Fig 7). This interaction impacts the link between aggregation and TDP-43 dysfunction, as reducing *ATXN2* expression decreases the accumulation of TDP-43 aggregates and rescues TDP-43 function upon aggregate seeding. These findings support the notion that the gain of toxic function caused by TDP-43 misfolding and the loss of its normal function are tightly connected processes. Importantly, they strongly suggest that inhibiting TDP-43 misfolding and aggregate accumulation may be an effective strategy to mitigate TDP-43 dysfunction and neurotoxicity.

Materials and methods

All chemicals and reagents were obtained from Millipore Sigma unless otherwise specified.

Cell culture and aggregate seeding assays—Material for aggregate seeding was obtained following sequential extraction from frontal cortex brain matter, according to previously established protocols for sequential fractionation to obtain a sarkosyl insoluble pellet [44]. Brain specimens were obtained from the Knight Alzheimer's Disease Research Center Pathology Core at Washington University in St. Louis. Briefly, approximately 100 mg of tissue was homogenized using a mini homogenizer (Pro-PK-01200S- ProScientific) in 0.5 mL of 1% Trixon X-100 (v:v) in high salt buffer (HS, 10 mM Tris–HCl, pH 7.4, 0.5 M NaCl, 2 mM EDTA, 10% sucrose (w:v), 1 mM DTT, and protease/phosphatase inhibitor cocktail). As in all fractionation steps, the first pellet was obtained upon ultracentrifugation, 180,000*g* for 30 min at 4°C. The first pellet was resuspended in 0.5 mL of 1% Trixon X-100 (v:v), 20% sucrose (w:v), 10 mM Tris–HCl, pH 7.4, 0.5 M NaCl, 2 mM EDTA, 1 mM DTT, protease/phosphatase inhibitors. The second pellet was solubilized in 0.1 mL of 50 mM Tris–HCl, pH 8.0, 20 mM NaCl, 2 mM MgCl2, and Benzonase (500 U/g tissue) and incubated for 20 min on ice. The third pellet was extracted with 2% sarkosyl (w:v), HS buffer and washed twice in 0.3 mL twice with phosphate buffered saline (PBS) and sonicated (Bioruptor Pico B0160010-Diagenode). The final pellet was resuspended in PBS to obtain approximately 0.1 μL/mg of initial tissue. The amount of TDP-43 in the extracts was estimated by immunoblotting using recombinant TDP-43 as control. The negative control, defined as neurologically unaffected control, brain corresponds to de-identified individuals defined these as cognitively unimpaired according to the Clinical Dementia Rating global score of 0, with minimal Alzheimer's disease-associated or other pathology.

HEK293^{FRET} and HEK-TDP^{NLS} cells were generated as previously described [21,35], maintained in DMEM (Dulbecco's Modified Eagle's Medium – High Glucose, Corning) supplemented with 10% FBS (Fetal Bovine Serum) and incubated in a humid atmosphere at 37°C and 5% CO_2. For the seeding assays, HEK293^{FRET} cells were plated in a 6-well plate at a density of 1×10^5 cells per well to achieve approximately 50% confluence after 24 h. HEK-TDP^{NLS} cells were plated (5×10^4 cells per well) to achieve approximately 25% confluence after 24 hours, then treated with 1 μg/μL tetracycline for 24 hours to induce mCherry-TDP-43 expression. Cells were then transfected with 0.5 μL of brain-derived sarkosyl-insoluble fraction and 5 μL of Lipofectamine 2000 transfection reagent (11,668−019, Invitrogen) per well in OPTI-MEM medium. After 24 hours, cells were trypsinized and replated for the indicated incubation time points. In the case of HEK-TDP^{NLS} cells tetracycline was maintained in the culture media.

iNeuron differentiation, culture and seeding assays—Isogenic iPSCs derived from the KOLF2.1J parental line, obtained from the iPSC Neurodegenerative Disease Initiative (iNDI), with a stably integrated tetracycline-inducible promoter, were cultured for 3 days in the presence of doxycycline (2 μg/ml). Cells were seeded at a density of $2x10^5$ cells/well in six-well plates coated with Matrigel in Dulbecco's modified Egle's medium (DMEM/F12) containing N2 supplement, Non-essential amino acids (NEAA), Glutamax and Y-27632. Medium was changed daily, and Y-27632 was removed after day 1. At day 4, pre-differentiated iNeurons were dissociated using Accutase, counted and plated at 1.5×10^6 cells/well in 6-well plates coated with Poly-L-ornithine (0.1 mg/ml) and Lamin (10 μg/ml) in maturation media. Maturation media consisted of 50% DMEM/F12, 50% Brainphys neural basal media, N21Max, GDNF (10 ng/ml), BDNF (10 ng/ml), NT-3 (10 ng/ml), Lamin (1 μg/ml), doxycycline (2 μg/ml). Half of the medium was replaced on day 7 and media changes were performed every 3

days thereafter using BrainPhys as the base medium. iNeurons were treated in 6-well plates ($n = 6$ per condition) on day 7 with 1 μl of brain-derived sarkosyl-insoluble fraction, either control or FTD seeds per well. Half of the media was replaced 3 days post-treatment, and neurons were maintained in culture for 2–3 weeks.

Immunofluorescence microscopy—Protein detection, visualization of mClover3 and mRuby3 signal and indirect immunofluorescence were performed according to previous methods [50] using the antibodies in S2 Table. Microscopy was carried out using a Keyence fluorescence microscope BZ-X series and confocal images were obtained using a Leica TCS SP8 microscope. High resolution images were obtained by stimulated emission depletion (STED) microscopy in a Leica SP8 TCS STED 3x Point Scanning Confocal microscope. TDP-43 levels were quantified using CellProfiler (v4.2.8) [81]. To quantify the intensity of nuclear TDP-43 levels, two grayscale channels were used for detection: DAPI (nuclear segmentation) and TDP-43. The *IdentifyPrimaryObjects* module with a Global *Thresholding Strategy*, declumping enabled, and an estimated diameter range of 30–200 μm, was used. Each TDP-43 punctum was associated with its parent nucleus using the *MeasureObjectIntensity* module to quantify per-cell intensity levels. Data were exported as spreadsheets using *ExportToSpreadSheet* module and processed in GraphPrism for statistical analysis. The pipeline and parameters were optimized using representative images and applied consistently across all experimental replicates. The same pipeline described above was used for whole-cell TDP-43 quantification, including the *IdentifySecondaryObjects* module following DAPI nuclear identification. Whole cells were identified in the TDP-43 channel by selecting nuclei as input objects, using the Propagation method for secondary objects detection, a Global as *Threshold Strategy*, and Minimum Cross Entropy as *Thresholding Method*. This enabled quantification of total TDP-43 intensity per cell.

Immunoblotting—Relative protein levels were measured by standard immunoblotting following preparation of cell lysates in 50 mM HEPES, pH 7.5, 0.5 M NaCl, 0.5% NP-40, 5% glycerol, 5 mM dithiothreitol (DTT), 1x SigmaFast EDTA-free protease inhibitor cocktail. Protein concentrations were determined using (bicinchoninic acid) BCA assay. Following SDS-PAGE, proteins were transferred onto a nitrocellulose membrane, and incubated with primary antibodies, listed in S2 Table, overnight at 4°C. Membranes were imaged using Odyssey scanning (LI-COR) and quantified using ImageStudio-Lite software (LICOR). Relative γH2AX levels were measured using enhanced chemiluminescence (ECL; Thermo Fisher Scientific, Cat. 32,106) according to the manufacturer's instructions.

Cell sorting and FRET quantification—Cells were rinsed and resuspended in phenol red-free DMEM for FRET quantification and FACS. FRET-positive cells were quantified using a FACSymphony A3 Cell Analyzer (BD Biosciences), equipped with 355, 405, 488, 561, and 637 nm lasers. The gating strategy for FRET quantification and sorting was based on analyses of stable HEK293 cells expressing mClover3-CTD or mRuby3-CTD only. This allowed us to establish the detection parameters. To measure mClover3 and FRET, cells were excited with the 488 nm laser and fluorescence was detected with a 530/30 nm and 610/20 bandpass filters, respectively. mRuby3 was excited with the 561 nm laser, and emission was collected using the 610/20 bandpass filter. For each sample, we evaluated at least 30,000 cells. Data analysis was performed using FACSDiva software, which quantified the percentage of FRET-positive cells based on the FRET signal intensity. FACS was performed on a FACSAria IIu SORP (BD Biosciences). Sorted cells were collected into 15 mL tubes containing DMEM; High Glucose, Corning, supplemented with 10% fetal bovine serum (FBS).

RNA transcript expression analysis—RNA extraction was carried out using Invitrogen Purelink RNA mini kit (12183018A). RNA was treated with Dnase I (EN0521-Thermo Scientific) to remove genomic DNA. RNA was extracted from iNeurons using the RNAeasy Mini Kit (7410-Qiagen), and genomic DNA was removed with Rnase-Free DNAse set (79254-Qiagen), following the manufacturer's instructions. cDNA synthesis and quantitative PCR were performed as previously described [82] using primers listed in S1 Table. Primers pairs to amplify *ARHGAP32* and *HDGFL2* without cryptic exons (S1 Table) recognized exons 12 and 13 and exons 6 and 7, respectively. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as housekeeping gene to normalize expression levels across samples.

siRNA-mediated knockdown—ATXN2 was downregulated in HEK293^{FRET} cells 48 h post-treatment with control or FTD seeds using ON-TARGETplus Human *ATXN2* siRNA-SMARTpool (Horizon Discovery L-011772-00-0005). Non-Targeting

siRNA #1 was used as negative control. siRNA was transfected using RNAimax (Invitrogen) according to manufacturer instructions.

Supporting information

S1 Fig. Preparation of aggregate extracts for seeding assays and accumulation of pTDP-43 in seeding reporter cells.
(PDF)

S2 Fig. Aggregates show characteristic filamentous morphology and expression of one CTD fusion protein is sufficient for de novo aggregation after seeding.
(PDF)

S3 Fig. Expression of both CTD pairs and treatment with TDP-43 proteinopathy-derived seeds are specifically required for seeding-induced FRET.
(PDF)

S4 Fig. Internalized FTD seeds do not contribute to antibody detection of mislocalized endogenous TDP-43 and γH2AX is correlated to nuclear TDP-43 levels.
(PDF)

S5 Fig. Effects of aggregate seeding on TDP-43 target regulation and expression of *ARHGAP32* and *HDGFL2* non-cryptic transcripts at early and later time points.
(PDF)

S6 Fig. Seeding-induced TDP-43 dysfunction in a non-CTD model.
(PDF)

S7 Fig. Endogenous TDP-43 protein levels are not significantly altered by aggregate seeding.
(PDF)

S8 Fig. G3BP1 and TIAR, stress granule proteins, do not significantly colocalize with seeding-induced TDP-43 aggregates.
(PDF)

S9 Fig. *ATXN2* downregulation decreases aggregation and TDP-43 loss of function in seeding biosensor cells.
(PDF)

S10 Fig. Immunofluorescence in mock-treated cells.
(PDF)

S1 Table. qPCR primers sequences.
(PDF)

S2 Table. List of antibodies used for immunoblotting and microscopy antibodies.
(PDF)

S1 Data. Data used to generate Fig 1E–-1G.
(XLSX)

S2 Data. Data used to generate Fig 2C.
(XLSX)

S3 Data. Data used to generate Fig 3B–C.
(XLSX)

S4 Data. Data used to generate Fig 4B–4D and 4F–G.
(XLSX)

S5 Data. Data used to generate Fig 5B.
(XLSX)

S6 Data. Data used to generate Fig 7B–7C.
(XLSX)

S7 Data. Data used to generate S3B–S3C Fig.
(XLSX)

S8 Data. Data used to generate S5A–S5B Fig.
(XLSX)

S9 Data. Data used to generate S6B Fig.
(XLSX)

S10 Data. Data used to generate S7C Fig.
(XLSX)

S11 Data. Data used to generate S9A and S9C–S9D Fig.
(XLSX)

S1 Raw Images. Original and uncropped images for Figs 3B, S1A–S1B, S7B and S9B. Raw data used to generate flow cytometry graphs, depicted in Figs 1E and S3, are available in Ayala, Yuna; Diamond, Marc; Vaquer-Alicea, Jaime (2026), "Flow Cytometry Data for: A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanisms", Mendeley Data, V1, https://doi.org/10.17632/yh788t3bxy.1.
(PDF)

Acknowledgments

We thank participants and their families and the Knight Alzheimer Disease Research Center at Washington University who made this research possible.

Author contributions

Conceptualization: Lohany Dias Mamede, Miwei Hu, Jaime Vaquer-Alicea, Marc I. Diamond, Timothy M. Miller, Yuna M. Ayala.

Formal analysis: Amanda R. Titus, Patricia M. Passos, Erica Lantelme, Yuna M. Ayala.

Funding acquisition: Marc I. Diamond, Timothy M. Miller, Yuna M. Ayala.

Investigation: Lohany Dias Mamede, Miwei Hu, Rachel L. French, Paige A. Kirschner, Yuna M. Ayala.

Methodology: Lohany Dias Mamede, Miwei Hu, Jaime Vaquer-Alicea, Patricia M. Passos, Erica Lantelme.

Project administration: Yuna M. Ayala.

Supervision: Erica Lantelme, Yuna M. Ayala.

Writing – original draft: Yuna M. Ayala.

Writing – review & editing: Lohany Dias Mamede, Miwei Hu, Erica Lantelme, Timothy M. Miller, Yuna M. Ayala.

References

1. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–3. https://doi.org/10.1126/science.1134108 PMID: 17023659
2. Buratti E, Dörk T, Zuccato E, Pagani F, Romano M, Baralle FE. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001;20(7):1774–84. https://doi.org/10.1093/emboj/20.7.1774 PMID: 11285240
3. Mercado PA, Ayala YM, Romano M, Buratti E, Baralle FE. Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res. 2005;33(18):6000–10. https://doi.org/10.1093/nar/gki897 PMID: 16254078
4. Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14(4):452–8. https://doi.org/10.1038/nn.2778 PMID: 21358640
5. Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14(4):459–68. https://doi.org/10.1038/nn.2779 PMID: 21358643
6. Rot G, Wang Z, Huppertz I, Modic M, Lenče T, Hallegger M, et al. High-resolution RNA maps suggest common principles of splicing and polyadenylation regulation by TDP-43. Cell Rep. 2017;19(5):1056–67. https://doi.org/10.1016/j.celrep.2017.04.028 PMID: 28467899
7. Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349(6248):650–5. https://doi.org/10.1126/science.aab0983 PMID: 26250685
8. Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB. Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons. Cell Rep. 2019;27(5):1409-1421.e6. https://doi.org/10.1016/j.celrep.2019.04.003 PMID: 31042469
9. Melamed Z, López-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22(2):180–90. https://doi.org/10.1038/s41593-018-0293-z PMID: 30643298
10. Brown A-L, Wilkins OG, Keuss MJ, Kargbo-Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603(7899):131–7. https://doi.org/10.1038/s41586-022-04436-3 PMID: 35197628
11. Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603(7899):124–30. https://doi.org/10.1038/s41586-022-04424-7 PMID: 35197626
12. Seddighi S, Qi YA, Brown A-L, Wilkins OG, Bereda C, Belair C, et al. Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD. Sci Transl Med. 2024;16(734):eadg7162. https://doi.org/10.1126/scitranslmed.adg7162 PMID: 38277467
13. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–11. https://doi.org/10.1016/j.bbrc.2006.10.093 PMID: 17084815
14. Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503–27. https://doi.org/10.1093/brain/awz099 PMID: 31039256
15. Amador-Ortiz C, Lin W-L, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61(5):435–45. https://doi.org/10.1002/ana.21154 PMID: 17469117
16. Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, et al. Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol. 2016;131(4):571–85. https://doi.org/10.1007/s00401-016-1537-1 PMID: 26810071
17. Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol. 2014;127(6):811–24. https://doi.org/10.1007/s00401-014-1269-z PMID: 24659241
18. Meneses A, Koga S, O'Leary J, Dickson DW, Bu G, Zhao N. TDP-43 pathology in Alzheimer's Disease. Mol Neurodegener. 2021;16(1):84. https://doi.org/10.1186/s13024-021-00503-x PMID: 34930382
19. McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2010;69(9):918–29. https://doi.org/10.1097/NEN.0b013e3181ee7d85 PMID: 20720505
20. McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(Pt 1):43–64. https://doi.org/10.1093/brain/aws307 PMID: 23208308
21. French RL, Grese ZR, Aligireddy H, Dhavale DD, Reeb AN, Kedia N, et al. Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation. J Biol Chem. 2019;294(17):6696–709. https://doi.org/10.1074/jbc.RA118.005889 PMID: 30824544
22. Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102(2):339-357.e7. https://doi.org/10.1016/j.neuron.2019.02.038 PMID: 30853299
23. Tamaki Y, Ross JP, Alipour P, Castonguay C-É, Li B, Catoire H, et al. Spinal cord extracts of amyotrophic lateral sclerosis spread TDP-43 pathology in cerebral organoids. PLoS Genet. 2023;19(2):e1010606. https://doi.org/10.1371/journal.pgen.1010606 PMID: 36745687
24. Lynch EM, Pittman S, Daw J, Ikenaga C, Chen S, Dhavale DD, et al. Seeding-competent TDP-43 persists in human patient and mouse muscle. Sci Transl Med. 2024;16(775):eadp5730. https://doi.org/10.1126/scitranslmed.adp5730 PMID: 39602508
25. Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun. 2018;9(1):4220. https://doi.org/10.1038/s41467-018-06548-9 PMID: 30310141

26. Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20–38. https://doi.org/10.1002/ana.23937 PMID: 23686809
27. Jamshidi P, Kim G, Shahidehpour RK, Bolbolan K, Gefen T, Bigio EH, et al. Distribution of TDP-43 pathology in hippocampal synaptic relays suggests transsynaptic propagation in frontotemporal lobar degeneration. J Neuropathol Exp Neurol. 2020;79(6):585–91. https://doi.org/10.1093/jnen/nlaa029 PMID: 32388566
28. Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73(10):805–11. https://doi.org/10.1212/WNL.0b013e3181b6bbbd PMID: 19738176
29. Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 2014;127(3):423–39. https://doi.org/10.1007/s00401-013-1238-y PMID: 24407427
30. Kumar ST, Nazarov S, Porta S, Maharjan N, Cendrowska U, Kabani M, et al. Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage. Nat Neurosci. 2023;26(6):983–96. https://doi.org/10.1038/s41593-023-01341-4 PMID: 37248338
31. King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61–80. https://doi.org/10.1016/j.brainres.2012.01.016 PMID: 22445064
32. Arseni D, Hasegawa M, Murzin AG, Kametani F, Arai M, Yoshida M, et al. Structure of pathological TDP-43 filaments from ALS with FTLD. Nature. 2022;601(7891):139–43. https://doi.org/10.1038/s41586-021-04199-3 PMID: 34880495
33. Arseni D, Chen R, Murzin AG, Peak-Chew SY, Garringer HJ, Newell KL, et al. TDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP. Nature. 2023;620(7975):898–903. https://doi.org/10.1038/s41586-023-06405-w PMID: 37532939
34. Arseni D, Nonaka T, Jacobsen MH, Murzin AG, Cracco L, Peak-Chew SY, et al. Heteromeric amyloid filaments of ANXA11 and TDP-43 in FTLD-TDP type C. Nature. 2024;634(8034):662–8. https://doi.org/10.1038/s41586-024-08024-5 PMID: 39260416
35. Zhu J, Pittman S, Dhavale D, French R, Patterson JN, Kaleelurrrahuman MS, et al. VCP suppresses proteopathic seeding in neurons. Mol Neurodegener. 2022;17(1):30. https://doi.org/10.1186/s13024-022-00532-0 PMID: 35414105
36. Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK, et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134(1):65–78. https://doi.org/10.1007/s00401-017-1679-9 PMID: 28130640
37. Cairns NJ, Neumann M, Bigio EH, Holm IE, Troost D, Hatanpaa KJ, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol. 2007;171(1):227–40. https://doi.org/10.2353/ajpath.2007.070182 PMID: 17591968
38. Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, et al. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol. 2006;65(6):571–81. https://doi.org/10.1097/00005072-200606000-00005 PMID: 16783167
39. Geser F, Martinez-Lage M, Robinson J, Uryu K, Neumann M, Brandmeir NJ, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol. 2009;66(2):180–9. https://doi.org/10.1001/archneurol.2008.558 PMID: 19204154
40. Josephs KA, Stroh A, Dugger B, Dickson DW. Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol. 2009;118(3):349–58. https://doi.org/10.1007/s00401-009-0547-7 PMID: 19455346
41. Mackenzie IRA, Baborie A, Pickering-Brown S, Du Plessis D, Jaros E, Perry RH, et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol. 2006;112(5):539–49. https://doi.org/10.1007/s00401-006-0138-9 PMID: 17021754
42. Mackenzie IR, Neumann M. Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathol. 2017;134(1):79–96. https://doi.org/10.1007/s00401-017-1716-8 PMID: 28466142
43. Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol. 2006;169(4):1343–52. https://doi.org/10.2353/ajpath.2006.060438 PMID: 17003490
44. Porta S, Xu Y, Lehr T, Zhang B, Meymand E, Olufemi M, et al. Distinct brain-derived TDP-43 strains from FTLD-TDP subtypes induce diverse morphological TDP-43 aggregates and spreading patterns in vitro and in vivo. Neuropathol Appl Neurobiol. 2021;47(7):1033–49. https://doi.org/10.1111/nan.12732 PMID: 33971027
45. Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117(2):137–49. https://doi.org/10.1007/s00401-008-0477-9 PMID: 19125255
46. Hiji M, Takahashi T, Fukuba H, Yamashita H, Kohriyama T, Matsumoto M. White matter lesions in the brain with frontotemporal lobar degeneration with motor neuron disease: TDP-43-immunopositive inclusions co-localize with p62, but not ubiquitin. Acta Neuropathol. 2008;116(2):183–91. https://doi.org/10.1007/s00401-008-0402-2 PMID: 18584184
47. Furman JL, Holmes BB, Diamond MI. Sensitive detection of proteopathic seeding activity with FRET flow cytometry. J Vis Exp. 2015;(106):e53205. https://doi.org/10.3791/53205 PMID: 26710240
48. Conicella AE, Zerze GH, Mittal J, Fawzi NL. ALS mutations disrupt phase separation mediated by α-Helical structure in the TDP-43 low-complexity C-terminal domain. Structure. 2016;24(9):1537–49. https://doi.org/10.1016/j.str.2016.07.007 PMID: 27545621
49. Lim L, Wei Y, Lu Y, Song J. ALS-causing mutations significantly perturb the self-assembly and interaction with nucleic acid of the intrinsically disordered prion-like domain of TDP-43. PLoS Biol. 2016;14(1):e1002338. https://doi.org/10.1371/journal.pbio.1002338 PMID: 26735904

50. Ayala YM, Misteli T, Baralle FE. TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression. Proc Natl Acad Sci U S A. 2008;105(10):3785–9. https://doi.org/10.1073/pnas.0800546105 PMID: 18305152

51. Wood M, Quinet A, Lin Y-L, Davis AA, Pasero P, Ayala YM, et al. TDP-43 dysfunction results in R-loop accumulation and DNA replication defects. J Cell Sci. 2020;133(20):jcs244129. https://doi.org/10.1242/jcs.244129 PMID: 32989039

52. Hill SJ, Mordes DA, Cameron LA, Neuberg DS, Landini S, Eggan K, et al. Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proc Natl Acad Sci U S A. 2016;113(48):E7701–9. https://doi.org/10.1073/pnas.1611673113 PMID: 27849576

53. Mitra J, Guerrero EN, Hegde PM, Liachko NF, Wang H, Vasquez V, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc Natl Acad Sci U S A. 2019;116(10):4696–705. https://doi.org/10.1073/pnas.1818415116 PMID: 30770445

54. Estades Ayuso V, Pickles S, Todd T, Yue M, Jansen-West K, Song Y, et al. TDP-43-regulated cryptic RNAs accumulate in Alzheimer's disease brains. Mol Neurodegener. 2023;18(1):57. https://doi.org/10.1186/s13024-023-00646-z PMID: 37605276

55. Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22(2):167–79. https://doi.org/10.1038/s41593-018-0300-4 PMID: 30643292

56. Prudencio M, Humphrey J, Pickles S, Brown A-L, Hill SE, Kachergus JM, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020;130(11):6080–92. https://doi.org/10.1172/JCI139741 PMID: 32790644

57. Irwin KE, Jasin P, Braunstein KE, Sinha IR, Garret MA, Bowden KD, et al. A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS-FTD. Nat Med. 2024;30(2):382–93. https://doi.org/10.1038/s41591-023-02788-5 PMID: 38278991

58. Bryce-Smith S, Brown A-L, Mehta PR, Mattedi F, Mikheenko A, Barattucci S, et al. TDP-43 loss induces extensive cryptic polyadenylation in ALS/FTD. bioRxiv. 2024:2024.01.22.576625. https://doi.org/10.1101/2024.01.22.576625 PMID: 38313254

59. Fernandopulle MS, Prestil R, Grunseich C, Wang C, Gan L, Ward ME. Transcription factor-mediated differentiation of human iPSCs into neurons. Curr Protoc Cell Biol. 2018;79(1):e51. https://doi.org/10.1002/cpcb.51 PMID: 29924488

60. Wang C, Ward ME, Chen R, Liu K, Tracy TE, Chen X, et al. Scalable production of iPSC-derived human neurons to identify Tau-lowering compounds by high-content screening. Stem Cell Reports. 2017;9(4):1221–33. https://doi.org/10.1016/j.stemcr.2017.08.019 PMID: 28966121

61. Ayala YM, De Conti L, Avendaño-Vázquez SE, Dhir A, Romano M, D'Ambrogio A, et al. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30(2):277–88. https://doi.org/10.1038/emboj.2010.310 PMID: 21131904

62. Koyama A, Sugai A, Kato T, Ishihara T, Shiga A, Toyoshima Y, et al. Increased cytoplasmic TARDBP mRNA in affected spinal motor neurons in ALS caused by abnormal autoregulation of TDP-43. Nucleic Acids Res. 2016;44(12):5820–36. https://doi.org/10.1093/nar/gkw499 PMID: 27257061

63. Avendaño-Vázquez SE, Dhir A, Bembich S, Buratti E, Proudfoot N, Baralle FE. Autoregulation of TDP-43 mRNA levels involves interplay between transcription, splicing, and alternative polyA site selection. Genes Dev. 2012;26(15):1679–84. https://doi.org/10.1101/gad.194829.112 PMID: 22855830

64. Bembich S, Herzog JS, De Conti L, Stuani C, Avendaño-Vázquez SE, Buratti E, et al. Predominance of spliceosomal complex formation over polyadenylation site selection in TDP-43 autoregulation. Nucleic Acids Res. 2014;42(5):3362–71. https://doi.org/10.1093/nar/gkt1343 PMID: 24369426

65. Weskamp K, Barmada SJ. TDP43 and RNA instability in amyotrophic lateral sclerosis. Brain Res. 2018;1693(Pt A):67–74. https://doi.org/10.1016/j.brainres.2018.01.015 PMID: 29395044

66. Rummens J, Khalil B, Yıldırım G, Silva P, Zorzini V, Peredo N, et al. TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43. Neuron. 2025;113(10):1597-1613.e8. https://doi.org/10.1016/j.neuron.2025.03.004 PMID: 40157356

67. Buratti E, Brindisi A, Giombi M, Tisminetzky S, Ayala YM, Baralle FE. TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem. 2005;280(45):37572–84. https://doi.org/10.1074/jbc.M505557200 PMID: 16157593

68. D'Ambrogio A, Buratti E, Stuani C, Guarnaccia C, Romano M, Ayala YM, et al. Functional mapping of the interaction between TDP-43 and hnRNP A2 in vivo. Nucleic Acids Res. 2009;37(12):4116–26. https://doi.org/10.1093/nar/gkp342 PMID: 19429692

69. Ling S-C, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, et al. ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A. 2010;107(30):13318–23. https://doi.org/10.1073/pnas.1008227107 PMID: 20624952

70. Watanabe R, Higashi S, Nonaka T, Kawakami I, Oshima K, Niizato K, et al. Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions. Acta Neuropathol Commun. 2020;8(1):176. https://doi.org/10.1186/s40478-020-01055-9 PMID: 33115537

71. Lu S, Hu J, Arogundade OA, Goginashvili A, Vazquez-Sanchez S, Diedrich JK, et al. Heat-shock chaperone HSPB1 regulates cytoplasmic TDP-43 phase separation and liquid-to-gel transition. Nat Cell Biol. 2022;24(9):1378–93. https://doi.org/10.1038/s41556-022-00988-8 PMID: 36075972

72. Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069–75. https://doi.org/10.1038/nature09320 PMID: 20740007

73. Wijegunawardana D, Vishal SS, Venkatesh N, Gopal PP. Ataxin-2 polyglutamine expansions aberrantly sequester TDP-43, drive ribonucleoprotein condensate transport dysfunction and suppress local translation. bioRxiv. 2023;:2023.01.30.526372. https://doi.org/10.1101/2023.01.30.526372 PMID: 36778347

74. Becker LA, Huang B, Bieri G, Ma R, Knowles DA, Jafar-Nejad P, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544(7650):367–71. https://doi.org/10.1038/nature22038 PMID: 28405022

75. Scialò C, Zhong W, Jagannath S, Wilkins O, Caredio D, Hruska-Plochan M, et al. Seeded aggregation of TDP-43 induces its loss of function and reveals early pathological signatures. Neuron. 2025;113(10):1614-1628.e11. https://doi.org/10.1016/j.neuron.2025.03.008 PMID: 40157355

76. Brown A-L, Wilkins OG, Keuss MJ, Kargbo-Hill SE, Zanovello M, Lee WC, et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603(7899):131–7. https://doi.org/10.1038/s41586-022-04436-3 PMID: 35197628

77. Ma XR, Prudencio M, Koike Y, Vatsavayai SC, Kim G, Harbinski F, et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene UNC13A. Nature. 2022;603(7899):124–30. https://doi.org/10.1038/s41586-022-04424-7 PMID: 35197626

78. Prudencio M, Humphrey J, Pickles S, Brown A-L, Hill SE, Kachergus JM, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest. 2020;130(11):6080–92. https://doi.org/10.1172/JCI139741 PMID: 32790644

79. Gittings LM, Alsop EB, Antone J, Singer M, Whitsett TG, Sattler R, et al. Cryptic exon detection and transcriptomic changes revealed in single-nuclei RNA sequencing of C9ORF72 patients spanning the ALS-FTD spectrum. Acta Neuropathol. 2023;146(3):433–50. https://doi.org/10.1007/s00401-023-02599-5 PMID: 37466726

80. Streit L, Kuhn T, Vomhof T, Bopp V, Ludolph AC, Weishaupt JH, et al. Stress induced TDP-43 mobility loss independent of stress granules. Nat Commun. 2022;13(1):5480. https://doi.org/10.1038/s41467-022-32939-0 PMID: 36123343

81. Stirling DR, Swain-Bowden MJ, Lucas AM, Carpenter AE, Cimini BA, Goodman A. CellProfiler 4: improvements in speed, utility and usability. BMC Bioinformatics. 2021;22(1):433. https://doi.org/10.1186/s12859-021-04344-9 PMID: 34507520

82. Koehler LC, Grese ZR, Bastos ACS, Mamede LD, Heyduk T, Ayala YM. TDP-43 oligomerization and phase separation properties are necessary for autoregulation. Front Neurosci. 2022;16:818655. https://doi.org/10.3389/fnins.2022.818655 PMID: 35495061